Biologics Manufacturing Asia 2026

The 13th Annual Biologics Manufacturing Asia 2026 is Asia’s premier bioprocessing-focused conference, providing a dedicated platform for regional biopharmaceutical industry stakeholders to network, explore strategic collaborations, and gain insights into the latest manufacturing technologies and advancements.

Co-hosted with BMA 2026, the ADC Asia Congress 2026 emerges as a pivotal gathering in the rapidly evolving Antibody Drug Conjugate industry, where Asia is establishing itself as the epicenter of next-generation ADC development. The congress will unite 40+ industry experts and 300+ attendees from Singapore, China, Japan, South Korea, Australia, and the broader Asia-Pacific region to explore technological innovations, clinical developments, and strategic collaborations in ADC advancement. The event, co-located with several other prestigious biologics conferences, will address critical industry challenges including high development costs and manufacturing complexities, while showcasing breakthrough technologies, real-world applications, and poster presentations highlighting the latest R&D developments. This comprehensive platform reflects the industry's response to increasing global cancer rates and the growing demand for advanced therapeutic options, supported by rising investments and FDA approvals.

Program